BioArctic Dirección

Dirección controles de criterios 3/4

El CEO de BioArctic es Gunilla Osswald , nombrado en Jan 2014, tiene una permanencia de 10.83 años. compensación anual total es SEK22.38M, compuesta por 19.8% salario y 80.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.11% de las acciones de la empresa, por valor de SEK18.38M. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 6.8 años, respectivamente.

Información clave

Gunilla Osswald

Chief Executive Officer (CEO)

SEK 22.4m

Compensación total

Porcentaje del salario del CEO	19.8%
Permanencia del CEO	10.8yrs
Participación del CEO	0.1%
Permanencia media de la dirección	5.8yrs
Promedio de permanencia en la Junta Directiva	6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Gunilla Osswald en comparación con los beneficios de BioArctic?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-SEK 233m
Jun 30 2024	n/a	n/a	-SEK 88m
Mar 31 2024	n/a	n/a	-SEK 122m
Dec 31 2023	SEK 22m	SEK 4m	SEK 229m
Sep 30 2023	n/a	n/a	SEK 259m
Jun 30 2023	n/a	n/a	SEK 270m
Mar 31 2023	n/a	n/a	SEK 327m
Dec 31 2022	SEK 9m	SEK 5m	-SEK 11m
Sep 30 2022	n/a	n/a	SEK 28m
Jun 30 2022	n/a	n/a	-SEK 147m
Mar 31 2022	n/a	n/a	-SEK 135m
Dec 31 2021	SEK 5m	SEK 3m	-SEK 120m
Sep 30 2021	n/a	n/a	-SEK 114m
Jun 30 2021	n/a	n/a	-SEK 97m
Mar 31 2021	n/a	n/a	-SEK 101m
Dec 31 2020	SEK 5m	SEK 3m	-SEK 69m
Sep 30 2020	n/a	n/a	-SEK 72m
Jun 30 2020	n/a	n/a	-SEK 60m
Mar 31 2020	n/a	n/a	SEK 78m
Dec 31 2019	SEK 7m	SEK 3m	SEK 88m
Sep 30 2019	n/a	n/a	SEK 441m
Jun 30 2019	n/a	n/a	SEK 475m
Mar 31 2019	n/a	n/a	SEK 380m
Dec 31 2018	SEK 5m	SEK 3m	SEK 382m
Sep 30 2018	n/a	n/a	SEK 58m
Jun 30 2018	n/a	n/a	SEK 32m
Mar 31 2018	n/a	n/a	SEK 29m
Dec 31 2017	SEK 3m	SEK 2m	SEK 15m

Compensación vs. Mercado: La compensación total ($USD2.03M) de Gunilla está en línea con el promedio de empresas de tamaño similar en el mercado UK ($USD2.22M).

Compensación vs. Ingresos: La compensación de Gunilla ha aumentado mientras la empresa no es rentable.

CEO

Gunilla Osswald (63 yo)

10.8yrs

Permanencia

SEK 22,378,000

Compensación

Dr. Gunilla Osswald, PhD has been the Chief Executive Officer and President of BioArctic AB (publ) since 2014. Dr. Osswald has been a Director of Egetis Therapeutics AB (publ) (formerly known as PledPharma...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gunilla Osswald	President & CEO	10.8yrs	SEK 22.38m	0.11% SEK 18.4m
Pär Gellerfors	Co-Founder	21.8yrs	SEK 390.00k	sin datos
Lars Lannfelt	Co-Founder	21.8yrs	SEK 2.54m	33.41% SEK 5.7b
Anders Martin-Lof	Chief Financial Officer	1.5yrs	sin datos	sin datos
Johanna Fälting	Chief Research Officer & Head of Research	no data	sin datos	0.051% SEK 8.7m
Christer Möller	VP of Pre-Clinical Development & Chief Scientific Officer	18.8yrs	sin datos	0.063% SEK 10.8m
Oskar Bosson	VP and Head of IR & Communication	4.5yrs	sin datos	0.016% SEK 2.8m
Leif Gallo	General Counsel and Head of Legal & IP	no data	sin datos	sin datos
Harald Borgeke	Head of Public Affairs	2.6yrs	sin datos	sin datos
Frida Lekander	Head of Marketing	2.8yrs	sin datos	sin datos
Gunilla Andersson	Vice President of Human Resources	5.8yrs	sin datos	sin datos
Mikael Moge	VP & Head of CMC	no data	sin datos	0.011% SEK 1.8m

5.8yrs

Permanencia media

63yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0RV2 es experimentado (5.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pär Gellerfors	Co-Founder	21.8yrs	SEK 390.00k	sin datos
Lars Lannfelt	Co-Founder	21.8yrs	SEK 2.54m	33.41% SEK 5.7b
Eugen Steiner	Independent Chairman	7.2yrs	SEK 621.00k	0.10% SEK 17.3m
Hans Wigzell	Member of Scientific Advisory Board	no data	sin datos	sin datos
Konrad Beyreuther	Member of the Scientific Board	no data	sin datos	sin datos
Marie Edström	Independent Director	1.4yrs	SEK 187.00k	sin datos
Mikael Smedeby	Independent Director	6.5yrs	SEK 316.00k	0.032% SEK 5.5m
Charlotta Ljungqvist	Independent Director	3.5yrs	SEK 318.00k	0.0036% SEK 613.3k
Martin Ingelsson	Member of Scientific Board	no data	sin datos	sin datos
Staffan Pauli	Member of Scientific Advisory Board	no data	sin datos	sin datos
Ken Marek	Member of Scientific Advisory Board	no data	sin datos	sin datos
Kaj Blennow	Member of Scientific Advisory Board	no data	sin datos	sin datos

6.8yrs

Permanencia media

70yo

Promedio de edad

Junta con experiencia: La junta directiva de 0RV2 se considera experimentada (6.8 años de antigüedad promedio).

BioArctic Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

BioArctic AB (publ) Presents Nomination Committee

BioArctic AB (publ), Annual General Meeting, May 22, 2025

Insufficient new directors

Insider recently sold kr710k worth of stock

Independent Chairman recently bought kr1.1m worth of stock

VP & Head of Research recently sold kr2.8m worth of stock

Recent updates

Third quarter 2024 earnings released: kr0.22 loss per share (vs kr1.42 profit in 3Q 2023)

Eisai Co., Ltd. and BioAge Labs, Inc. Announce CHMP Issues Positive Recommendation for Approval of Lecanemab in the EU

BioArctic AB (publ) to Report Q2, 2025 Results on Aug 28, 2025

BioArctic AB (publ) Presents Nomination Committee

BioArctic AB (publ), Annual General Meeting, May 22, 2025

Second quarter 2024 earnings released: kr0.77 loss per share (vs kr1.16 loss in 2Q 2023)

BioArctic AB (publ) Announces Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology

Insufficient new directors

Insider recently sold kr710k worth of stock

BioArctic AB (publ) Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South Korea

First quarter 2024 earnings released

Full year 2023 earnings released: EPS: kr2.60 (vs kr0.13 loss in FY 2022)

New minor risk - Share price stability

BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders

Full year 2023 earnings released: EPS: kr2.60 (vs kr0.13 loss in FY 2022)

The European Medicines Agency's Scientific Advisory Group (SAG) to Discuss the Marketing Authorisation Application for lecanemab

Independent Chairman recently bought kr1.1m worth of stock

Third quarter 2023 earnings released: EPS: kr1.42 (vs kr1.55 in 3Q 2022)

BioArctic AB's (publ) Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI

VP & Head of Research recently sold kr2.8m worth of stock

VP & Head of Research recently sold kr2.8m worth of stock

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Parkinson's Disease

Second quarter 2023 earnings released: kr1.16 loss per share (vs kr0.52 loss in 2Q 2022)

BioArctic AB (publ) to Report Q3, 2024 Results on Nov 14, 2024

Eisai Announces Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Files in South Korea

Vice President of Communications & IR recently sold kr1.7m worth of stock

BioArctic AB (publ) Approves Board Changes

Eisai Announces Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

VP & Head of Research recently sold kr6.5m worth of stock

Insider recently bought kr241k worth of stock

First quarter 2023 earnings released

Independent Director recently sold kr3.3m worth of stock

BioArctic AB (publ) Announces Board Changes

Full year 2022 earnings released: kr0.13 loss per share (vs kr1.36 loss in FY 2021)

Bioarctic AB's (Publ) Partner Eisai Announces that European Medicines Agency Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

BioArctic AB (publ) Announces Wenche Rolfsen Declines Re-Election to the Board

BioArctic AB (publ) Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI for the Treatment of Alzheimer's Disease

Bioarctic AB's (Publ) Partner Eisai Presents Results from lecanemab Confirmatory Phase 3 Clarity Ad Study

BioArctic AB (publ) Expands Portfolio with Alpha-Synuclein Brain Transporter Project

Insufficient new directors

BioArctic develops New treatment for Gaucher's Disease

Third quarter 2022 earnings released: EPS: kr1.55 (vs kr0.43 loss in 3Q 2021)

BioArctic AB (publ) to Report Q3, 2023 Results on Nov 08, 2023

BioArctic AB (publ), Annual General Meeting, Jun 01, 2023

Bioarctic Ab's (Publ) Announces Positive Topline Results for the Large Global Phase 3 Confirmatory Clarity Ad Study in 1,795 Subjects

Bioarctic AB (Publ) Announces Latest Data on Lecanemab Presented At Alzheimer's Association International Conference (Aaic)

Second quarter 2022 earnings released: kr0.52 loss per share (vs kr0.39 loss in 2Q 2021)

Insider recently bought kr100k worth of stock

First quarter 2022 earnings released

Insufficient new directors

Full year 2021 earnings released: kr1.36 loss per share (vs kr0.78 loss in FY 2020)

Independent Deputy Chairman recently bought kr824k worth of stock

Bioarctic AB Announces Executive Changes

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioArctic AB (publ) to Report Fiscal Year 2021 Final Results on Mar 31, 2022

DIAN-TU Enrolls First Subject for the Tau Nexgen Study with Lecanemab as Back-Ground Anti-Amyloid Treatment

Bioarctic AB (Publ) Announces Lecanemab Granted Fast Track Designation by the FDA

Third quarter 2021 earnings released

BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

Chief Medical Officer recently bought kr103k worth of stock

BioArctic AB (publ) Receives Patent in Japan for New Antibodies Targeting Alzheimer's Disease

Independent Director has left the company

First quarter 2021 earnings released: kr0.33 loss per share (vs kr0.04 profit in 1Q 2020)

Bioarctic and Eisai Present Latest Data Regarding Lecanemab at AD/PD 2021

Bioarctic AB (Publ) and Eisai to Present Data Relating to Its Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody Lecanemab (BAN2401)

BioArctic AB (publ) Announces Board Changes

Full year 2020 earnings released: kr0.78 loss per share (vs kr1.01 profit in FY 2019)

Revenue beats expectations

BioArctic AB (publ) to Report Fiscal Year 2020 Final Results on Mar 31, 2021